CD274 and non-small cell lung carcinoma: ICI was administered in 78% of the patients as 1 L and in 22% as ≥2 L. Significant differences in PS, PD-L1 TPS, NSCLC histopathological subtype, lung metastases, and peripheral lymph node metastases were observed between patients treated with 1 L and ≥2 L ICI.